font size
Sign inprintPrint
The Burrill Weekly Brief | July 15, 2013

 
Though the advent of personalized medicine and the changing way doctors treat and manage disease has been most apparent in the area of cancer, new molecular diagnostics are transforming care in many other disease areas. Crescendo Bioscience’s Vectra DA test for rheumatoid arthritis is one such example. We spoke to Crescendo CEO Bill Hagstrom about the test, how it’s changing the way physicians manage and treat RA patients, and how the company has addressed the challenges of adoption and reimbursement. Read More Here
  • Myriad decision
  • Bowman v. Monsanto
  • DNA and Law Enforcement
By The Numbers
Biggest movers for the week ending July 12, 2013
TICKER
COMPANY
CLOSING PRICE 7/5/2013
CLOSING PRICE 7/12/2013
PRICE CHANGE
PERCENT CHANGE
 
ADVANCERS
ADHD
Alcobra 
6.84
10.69
3.85
56.3%
NasdaqGS:RNA
Prosensa 
19.65
27.75
8.10
41.2%
ALNY
Alnylam Pharmaceuticals
37.82
50.04
12.22
32.3%
PGNX
Progenics Pharmaceuticals
4.61
5.79
1.18
25.6%
ATHN
Athenahealth
87.75
109.75
22.00
25.1%
DECLINERS
CERE
Ceres
3.29
2.34
-0.95
-28.9%
MACK
Merrimack Pharmaceuticals
7.00
5.08
-1.92
-27.4%
CRMD
CorMedix
1.18
0.89
-0.29
-24.6%
JASDAQ:4978
ReproCell
15730
12550
-3180
-20.2%
NasdaqCM:NEO
Neogenomics 
3.95
3.23
-0.72
-18.2%
Includes life sciences stocks with closing price of $1 or more on July 5, 2013,
Sorghum Proves Ho Hum For Ceres
Economies around the globe remain weak, with the International Monetary Fund trimming its global-growth forecast and reducing its projections for emerging markets, such as China and Russia. In the United States, Federal Reserve Chairman Ben Bernanke cited the high unemployment rate, the low inflation rate, and growth-dampening fiscal policies as factors contributing to the Fed’s decision to continue economic supports. That news boosted The Dow Jones Industrial Average up 2.2 percent, the S&P 500 up 3.0 percent, and the Nasdaq Composite up 3.5 percent. Biotech beat the major market indices as the Burrill Select index up 6.2 percent.

Alcobra was the week’s biggest advancer, up 56.3 percent from $6.84 to $10.69 per share, after Aegis Capital initiated coverage with a price target of $30 per share.

Ceres was the biggest decliner, down 28.9 percent after management said it anticipates that many of its mill customers will repeat smaller scale commercial plantings of sweet sorghum before committing to broad, large-scale adoption. Several analysts downgraded the stock following the announcement.


Loxo Oncology Strikes $434 M Cancer Deal with Array BioPharma
In a reversal of the standard story of a big company licensing a compound from a small company, newly formed Loxo Oncology is teaming up with Array BioPharma in deal that could be worth up to $434 million for Array. Read More Here
Collaboration focuses on small molecule therapies for genetically defined patient populations.
BURRILL INDICES
12/31/2012
7/5/2013
7/12/2013
Week Change
Year Change
Burrill Select
589.98
812.86
863.05
6.2%
46.3%
Burrill Large Cap
711.61
994.62
1060.15
6.6%
49.0%
Burrill Mid-Cap
309.52
407.87
435.86
6.9%
40.8%
Burrill Small Cap
105.48
141.52
151.20
6.8%
43.3%
Burrill Diagnostics
191.32
210.76
214.49
1.8%
12.1%
Burrill Personalized Medicine
118.52
149.33
151.05
1.2%
27.4%
Burrill Biogreentech
163.09
177.29
184.81
4.2%
13.3%
NASDAQ
3019.51
3479.38
3600.08
3.5%
19.2%
DJIA
13104.14
15135.84
15464.30
2.2%
18.0%
S&P 500
1426.19
1631.89
1680.19
3.0%
17.8%
Amex Biotech
1547.03
2036.95
2178.67
7.0%
40.8%
Amex Pharmaceutical
369.57
418.60
431.79
3.2%
16.8%
NASDAQ Biotechnology Index
1430.81
1900.59
2017.25
6.1%
41.0%
 
FDA Plans to Give Generic Drugmakers Power to Change Labels
Consumer advocates hail move that could improve safety for patients and create liability for companies.
The U.S. Food and Drug Administration is seeking to to end restrictions on labeling revisions by generic drugmakers, a move that consumer advocates say would close a gap that threatens patient health and safety and make companies more accountable. Read More Here
Bio-based Industries to Get $5 Billion Boost from European Commission
EU Initiative is part of $28.7 billion investment to create high-tech jobs and growth over next seven years.
The European Commission has announced the formation of a public-private partnership worth almost $5 billion (3.8 billion euros) over seven years to boost growth and jobs in the European bio-based industrial sector. Read More Here
Italian Pharma Backs UniQure’s Gene Therapy
Rights deal will cover Glybera development costs, fuel progress on pipeline.
UniQure says it has signed two new collaboration agreements with Chiesi Farmaceutici for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. Read More Here
Senate Seeks to Grow NIH Budget for Fiscal 2014
Expanded spending plan could ease some sequester-driven cuts.
The National Institutes of Health could see sequester-driven budget cuts reversed and funding for medical research increased under a fiscal 2014 budget approved by a U.S Senate committee. Read More Here
Forma Therapeutics Teams with Cancer Research Technology
Deal is part of broader translational medicine initiative based on company’s asset discovery and development company model.
Forma Therapeutics is teaming up with academic researchers affiliated with Cancer Research UK to discover drugs targeting protein homeostasis regulators, an important pathway in diseases such as cancer and neurodegenerative disorders. Read More Here
Novartis Strikes Vaccines Deal with Biological E
Through WHO, companies target typhoid and paratyphoid in emerging markets.
Novartis is handing off two new vaccines to India’s Biological E for manufacturing, further clinical development, approval, and distribution in the developing world. Read More Here
Fighting the Flu without Vaccines
Systems biology approach points to drug targets for influenza.
Researchers at Seattle BioMed, together with collaborators at the University of California, San Diego School of Medicine, St. Jude Children’s Research Hospital, and the University of Washington have found a new potential target for drug development in the fight against flu. Read More Here
China Arrests GSK Employees for Alleged Bribery and Tax Violations
The weekly round-up of failed trials, missed targets, and other business mishaps.
China's Ministry of Public security has arrested at least 30 employees of GlaxoSmithKline, including some senior executives, for alleged bribery and tax violations. GSK says that recent details released by the ministry provided its first official insight into the matter and that the company had not detected bribery through its own internal monitoring. Read More Here
All-in-one
 
Reach nearly 25,000 life sciences thought
leaders each week:
To advertise in The Weekly Brief contact our business development team by clicking here
You are receiving this email because you have subscribed to the Weekly Brief or previously expressed an interest in The Burrill Report or other Burrill & Company publications or events.

 

 
Don't forget to join us on
 
HOMEPAGE | Click Here to subscribe to The Burrill Weekly Brief
Archive
The Burrill Weekly Brief | October 14, 2013
The Burrill Weekly Brief | October 07, 2013
The Burrill Weekly Brief | September 30, 2013
The Burrill Weekly Brief | September 23, 2013
The Burrill Weekly Brief | September 16, 2013
The Burrill Weekly Brief | September 03, 2013
The Burrill Weekly Brief | August 19, 2013
The Burrill Weekly Brief | August 12, 2013
The Burrill Weekly Brief | August 05, 2013
The Burrill Weekly Brief | July 29, 2013

The Life Sciences Delivered to Your Desktop Every Monday Morning


 

Click Here for a FREE subscription to The Burrill Weekly Brief

Sign Up to recevie the Burrill Weekly Brief


Follow burrillreport on Twitter